Fuda Cancer Hospital
Hormone therapy in China typically costs from $3,500 to $9,800. The final price depends on the medical condition, medication form, and the clinical setting. Patients save around 39% compared to the US, where this treatment costs $11,000 on average. Inclusions generally cover initial consultations and diagnostic hormone profiling at specialized medical centers.
Bookimed Expert Insight: Choosing specialized oncology centers like Fuda Cancer Hospital provides significant value. This JCI-accredited facility in Guangzhou treats over 30,000 international patients. It focuses on minimally invasive therapies instead of traditional chemotherapy. For hormone-sensitive cancers, this approach combines high-tech diagnostics with tailored endocrine protocols. This strategy often yields better results for late-stage patients than standard medication alone.
| China | Turkey | Austria | |
| Hormone therapy | from $3,500 | from $406 | from $7,000 |
| Androgen deprivation therapy | from $3,800 | from $1,500 | from $4,500 |
| Hormone therapy for prostate cancer | - | from $1,200 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Hormone therapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Hormone therapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Hormone therapy journey.
Day 1 - Arrival
Day 2 - Pre-operation Consultation
Day 3 - Test Results and Treatment Plan
Day 4 - Start of Hormone Therapy
Day 5 to 14 - Continuation of Therapy
Week 3 - Post-operation Monitoring
Week 4 - Rehabilitation
Week 6
Week 8
Please note that this is a general guide and individual experiences may vary. Always consult your healthcare provider for personalized advice.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Menopausal hormone therapy in China is historically uncommon, with uptake rates among postmenopausal women typically ranging from 2% to 3%. While usage is currently surging in major urban centers, traditional cultural perspectives and safety concerns regarding oncological risks often limit broader clinical adoption.
Bookimed Expert Insight: While overall national rates remain low, international-standard facilities like JCI-accredited Fuda Cancer Hospital demonstrate how Chinese medical infrastructure integrates advanced hormonal monitoring. Patients seeking this therapy should target Tier-1 cities like Guangzhou or Shanghai. Research indicates that private clinics and oncology centers often provide more specialized endocrine screening than smaller regional hospitals.
Patient Consensus: Many women report being told to simply endure symptoms as a natural life stage. Patients often must advocate strongly for themselves or seek international-friendly clinics to access modern Western formulations.
Gender-affirming hormone therapy is legally available in China but subject to strict centralized regulation. Patients must obtain a formal gender dysphoria diagnosis from a licensed psychiatrist before accessing treatment. Prescriptions are primarily managed through specialized clinics in major metropolitan hubs like Shanghai, Beijing, and Guangzhou.
Bookimed Expert Insight: Legality in China is highly dependent on individual hospital policy rather than a single national mandate. While facilities like the Childrens Hospital of Fudan University pave the way, clinicians often interpret rules differently. If one provider refuses care, seeking a second opinion at a Joint Commission International-accredited facility in a different city is a common and effective strategy.
Patient Consensus: The process often feels like proving legitimacy through exhausting paperwork rather than informed consent. Many patients emphasize that navigating the formal hospital system is emotionally draining but critical for ensuring medication quality and proper bloodwork monitoring.
Transgender individuals cannot legally purchase hormone replacement therapy medications online in China. National regulations enacted in December 2022 strictly prohibit the e-commerce sale of estradiol, cyproterone acetate, and testosterone. Valid hospital prescriptions do not override this absolute ban for online retail platforms.
Bookimed Expert Insight: While hospital-based therapy costs $3,500 to $9,800, the real barrier is geographical. Specialized clinics are concentrated in Beijing and Shanghai, leaving patients in other provinces without stable, regulated medication access.
Patient Consensus: Many individuals face dangerous supply interruptions through unregulated sellers. Patients emphasize that maintaining a consistent dose is nearly impossible without a local hospital connection.
Menopause treatment in China integrates Western hormonal therapy with Traditional Chinese Medicine to manage vasomotor symptoms and insomnia. Common prescriptions include estradiol-based compounds like Femoston, tibolone for women aged 51–60, and herbal proprietary medicines such as Kun-tai capsules or Liu Wei Di Huang Wan.
Bookimed Expert Insight: Chinese clinical practice significantly favors a conservative, integrated approach compared to Western protocols. Data suggests that combining Traditional Chinese Medicine with lower-dose Western hormones reduces adverse reactions while effectively managing symptoms. Patients often receive specific herbal formulas like Xiao Yao San alongside standard estradiol to address the psychological aspects of menopause.
Patient Consensus: Patients value how clinicians address specific complaints like sleep and bone protection rather than a one-size-fits-all pill. Many appreciate the availability of micronized progesterone for its sleep benefits despite occasional reports of vivid dreams.
Chinese women frequently integrate Traditional Chinese Medicine (TCM) with conventional hormone therapy, a practice known as integrated traditional Chinese and Western medicine. This combined approach manages symptoms like hot flashes and mood swings while reducing pharmaceutical side effects for menopause, infertility, and cancer recovery care.
Bookimed Expert Insight: While traditional methods are popular, specialized centers like Fuda Cancer Hospital in Guangzhou demonstrate the value of JCI-accredited oversight. Combining ancient herbal wisdom with advanced technologies like NanoKnife ensures that integrated treatments stay evidence-based. Patients should prioritize clinics that offer standardized, reputable traditional care instead of using unlabeled products for safety.
Patient Consensus: Patients emphasize that traditional treatments provide extra relief but warn about the importance of reporting all herbs to doctors. Most appreciate acupuncture for its perceived safety profile compared to the unpredictability of some herbal products.